Anew Medical, Inc.
Anew Medical, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic par… Read more
Anew Medical, Inc. (WENA) - Net Assets
Latest net assets as of June 2024: $-1.55 Million USD
Based on the latest financial reports, Anew Medical, Inc. (WENA) has net assets worth $-1.55 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.31 Million) and total liabilities ($4.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.55 Million |
| % of Total Assets | -46.88% |
| Annual Growth Rate | 230.82% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 5515.35 |
Anew Medical, Inc. - Net Assets Trend (2021–2023)
This chart illustrates how Anew Medical, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Anew Medical, Inc. (2021–2023)
The table below shows the annual net assets of Anew Medical, Inc. from 2021 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $11.21 Million | -90.10% |
| 2022-12-31 | $113.32 Million | +10940.60% |
| 2021-12-31 | $1.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Anew Medical, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 473321600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $18.56 Million | 165.55% |
| Total Equity | $11.21 Million | 100.00% |
Anew Medical, Inc. Competitors by Market Cap
The table below lists competitors of Anew Medical, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Country Club Hospitality & Holidays Limited
NSE:CCHHL
|
$4.42 Million |
|
Quantum Genomics SA
PA:ALQGC
|
$4.43 Million |
|
Only World Group Holdings Bhd
KLSE:5260
|
$4.43 Million |
|
Patentus SA
WAR:PAT
|
$4.43 Million |
|
Prg Holdings Bhd
KLSE:7168
|
$4.42 Million |
|
Tincorp Metals Inc.
OTCQX:TINFF
|
$4.42 Million |
|
Signet Industries Limited
NSE:SIGIND
|
$4.42 Million |
|
Ravinder Heights Limited
NSE:RVHL
|
$4.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anew Medical, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 113,317,140 to 11,214,154, a change of -102,102,986 (-90.1%).
- Net income of 1,346,125 contributed positively to equity growth.
- Other comprehensive income increased equity by 117,362,498.
- Other factors decreased equity by 220,811,609.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.35 Million | +12.0% |
| Other Comprehensive Income | $117.36 Million | +1046.56% |
| Other Changes | $-220.81 Million | -1969.04% |
| Total Change | $- | -90.10% |
Book Value vs Market Value Analysis
This analysis compares Anew Medical, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.30x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 4.40x to 0.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $0.08 | $0.35 | x |
| 2022-12-31 | $7.60 | $0.35 | x |
| 2023-12-31 | $1.15 | $0.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anew Medical, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.00%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.73x
- Recent ROE (12.00%) is above the historical average (-31.65%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -108.05% | 0.00% | 0.00x | 1.01x | $-1.21 Million |
| 2022 | 1.09% | 0.00% | 0.00x | 1.04x | $-10.10 Million |
| 2023 | 12.00% | 0.00% | 0.00x | 1.73x | $224.71K |
Industry Comparison
This section compares Anew Medical, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anew Medical, Inc. (WENA) | $-1.55 Million | -108.05% | N/A | $4.42 Million |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |